Related Experiment Video
Updated: May 19, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Everolimus in pediatric transplantation
Lars Pape1, Rainer Ganschow, Thurid Ahlenstiel
1Department of Pediatric Nephrology, Hepatology and Metabolic Diseases, Hannover Medical School, Hannover, Germany. larspape@t-online.de
Insights
Everolimus offers significant benefits in pediatric organ transplantation, reducing toxicity and improving outcomes. This immunosuppressant shows promise for safer and more effective post-transplant care in children.
Area of Science:
- Immunology
- Pediatric Medicine
- Transplantation Science
Background:
- Solid-organ transplantation in children presents unique challenges regarding immunosuppression.
- Calcineurin inhibitors are standard but associated with significant toxicities.
- Novel immunosuppressive agents are needed to improve long-term outcomes in pediatric transplant recipients.
Purpose of the Study:
- To review current studies and clinical trials on everolimus in pediatric solid-organ transplantation.
- To evaluate the immunosuppressive effects and clinical outcomes of everolimus in children.
- To assess the safety and efficacy profile of everolimus in this population.
Main Methods:
- Systematic review of relevant literature and clinical trials.
- Analysis of studies focusing on immunosuppression in pediatric organ transplant recipients.
- Evaluation of efficacy, safety, and side-effect profiles.
Main Results:
- Everolimus use in pediatric organ transplantation is linked to reduced calcineurin inhibitor toxicity.
- Improved renal function and a low incidence of acute rejection were observed.
- Everolimus demonstrated an acceptable side-effect profile, decreasing viral infections and posttransplant lymphoproliferative disease risk.
Conclusions:
- Everolimus is an effective immunosuppressant for pediatric solid-organ transplantation with notable advantages.
- It offers benefits including reduced toxicity and improved patient outcomes.
- Further prospective, randomized controlled trials are warranted to confirm these findings.
Purpose Of Review:
The use of everolimus has recently emerged for solid-organ transplantation in children. This review gives an overview of the relevant studies and clinical trials involving the immunosuppressive effects of everolimus in child organ transplant.
Recent Findings:
The use of everolimus in pediatric organ transplantation is associated with a decrease in calcineurin inhibitor-related toxicity, better renal function, a low number of acute rejections, and an acceptable side-effect profile. Particularly, the use of everolimus reduces the incidence of virus infection and the risk of posttransplant lymphoproliferative disease.
Summary:
Everolimus is an effective agent with several advantages for pediatric solid-organ transplantation. Future prospective, randomized controlled trials will have to be performed in order to validate the findings of these pilot trials.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management

